Intensity Therapeutics IncNASDAQ:INTSNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE3.9250
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.8200/ 5
- Ask / Lots4.4000/ 20
- Open / Previous Close3.8200 / 3.9250
- Day Range
- 52 Week Range
- Volume8,191
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INTS |
|---|---|---|
| 09:32 ET | 100 | 3.82 |
| 10:10 ET | 4916 | 3.8427 |
| 10:12 ET | 100 | 3.965 |
| 10:35 ET | 700 | 3.94 |
| 01:12 ET | 200 | 3.8965 |
| 01:24 ET | 400 | 3.9 |
| 01:53 ET | 100 | 3.88 |
| 02:06 ET | 100 | 3.87 |
| 02:31 ET | 100 | 3.845 |
| 03:56 ET | 500 | 3.925 |
Apr 2, 2024
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024, from 8:01AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:01AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Intensity Therapeutics Inc | 53.8M | -4.5x | --- |
AVROBIO Inc | 54.3M | 4.4x | --- |
ARCA Biopharma Inc | 51.9M | -9.7x | --- |
Reneo Pharmaceuticals Inc | 55.8M | -0.7x | --- |
Immix Biopharma Inc | 56.2M | -2.4x | --- |
Eledon Pharmaceuticals Inc | 51.1M | -1.1x | --- |
Company Information
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.
Contact Information
- Headquarters
- 61 Wilton Road, 3Rd FloorWESTPORT, CT, United States 06880
- Phone
- 203-221-7381
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Lewis Bender
- Chief Financial Officer
- Joseph Talamo
- Executive Vice President - Corporate Finance
- James Ahlers
- Principal Accounting Officer, Controller
- John Wesolowski
- Independent Director
- Daniel Donovan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $53.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.87 |
Book Value | $0.96 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
